Prosensa maintains sunny outlook as drisapersen data trickle through
This article was originally published in Scrip
Executive Summary
Prosensa has reaffirmed its faith in its investigational Duchenne muscular dystrophy (DMD) therapy drisapersen, with updated Phase II results that it says lend further support to the idea that patients need to be treated earlier and for longer for best effect in delaying progression in the deadly disease.